デフォルト表紙
市場調査レポート
商品コード
1434967

強直性脊椎炎市場:医薬品、分子タイプ、作用機序、投与経路、剤形、エンドユーザー別-2024-2030年世界予測

Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
強直性脊椎炎市場:医薬品、分子タイプ、作用機序、投与経路、剤形、エンドユーザー別-2024-2030年世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強直性脊椎炎市場規模は2023年に51億8,000万米ドルと推計され、2024年には56億米ドルに達し、CAGR 8.31%で2030年には90億6,000万米ドルに達すると予測されます。

強直性脊椎炎の世界市場

主な市場の統計
基準年[2023] 51億8,000万米ドル
予測年[2024] 56億米ドル
予測年 [2030] 90億6,000万米ドル
CAGR(%) 8.31%
強直性脊椎炎 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは強直性脊椎炎市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、強直性脊椎炎市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-強直性脊椎炎市場の市場規模および予測は?

2-強直性脊椎炎市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-強直性脊椎炎市場における技術動向と規制の枠組みは?

4-強直性脊椎炎市場における主要ベンダーの市場シェアは?

5-強直性脊椎炎市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 強直性脊椎炎の発生率の増加
      • 病気の診断と治療に対する意識の高まり
      • 整形外科病院と診断センターの数の増加
    • 抑制要因
      • 高額な治療費と熟練した外科医や理学療法士の不足
    • 機会
      • 脊椎炎治療のための研究開発支出の加速
      • 強直性脊椎炎を治療するための生物学的製剤の登場
    • 課題
      • 既承認薬の特許失効に関する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 強直性脊椎炎市場薬物別

  • シムジア
  • コセンティクス
  • エンブレル
  • ヒュミラ
  • レミケード
  • シンポニ

第7章 強直性脊椎炎市場分子の種類別

  • 生物製剤
  • 低分子

第8章 強直性脊椎炎市場作用機序別

  • シクロオキシゲナーゼ阻害剤
  • 腫瘍壊死因子阻害剤

第9章 強直性脊椎炎市場:投与経路別

  • オーラル
  • 非経口

第10章 強直性脊椎炎市場剤形別

  • 液体
  • 固体

第11章 強直性脊椎炎市場:エンドユーザー別

  • クリニック
  • 病院

第12章 南北アメリカの強直性脊椎炎市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第13章 アジア太平洋地域の強直性脊椎炎市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第14章 欧州・中東・アフリカの強直性脊椎炎市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第15章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第16章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb
    • Celltrion Healthcare Co.,Ltd.
    • Eisai Co., Ltd
    • Eli Lilly and Company
    • Hetero Drugs Limited
    • Novartis AG
    • Reliance Life Sciences
    • Samsung Bioepis Co., Ltd.
    • Sandoz International GmbH
    • Sanofi-Aventis Groupe S.A.
    • Shanghai Pharmaceuticals Holding Co., Ltd.
    • Trinity Biotech PLC
    • Xian Janssen Pharmaceutical Ltd
  • 主要な製品ポートフォリオ

第17章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
  • FIGURE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
  • FIGURE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 28. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 22. ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 278. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 279. ANKYLOSING SPONDYLITIS MARKET LICENSE & PRICING
目次
Product Code: MRR-A339DAEFAAAE

[193 Pages Report] The Ankylosing Spondylitis Market size was estimated at USD 5.18 billion in 2023 and expected to reach USD 5.60 billion in 2024, at a CAGR 8.31% to reach USD 9.06 billion by 2030.

Global Ankylosing Spondylitis Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.18 billion
Estimated Year [2024] USD 5.60 billion
Forecast Year [2030] USD 9.06 billion
CAGR (%) 8.31%
Ankylosing Spondylitis Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Cimzia
    • Cosentyx
    • Enbrel
    • Humira
    • Remicade
    • Simponi
  • Type of Molecule
    • Biologics
    • Small Molecules
  • Mechanism Of Action
    • Cyclooxygenase Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Oral
    • Parenteral
  • Dosage Forms
    • Liquid
    • Solid
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Ankylosing Spondylitis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?

3. What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?

4. What is the market share of the leading vendors in the Ankylosing Spondylitis Market?

5. Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Ankylosing Spondylitis Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of ankylosing spondylitis
      • 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
      • 5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
    • 5.1.3. Opportunities
      • 5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
      • 5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to patent expiration of already approved drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Ankylosing Spondylitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Cimzia
  • 6.3. Cosentyx
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi

7. Ankylosing Spondylitis Market, by Type of Molecule

  • 7.1. Introduction
  • 7.2. Biologics
  • 7.3. Small Molecules

8. Ankylosing Spondylitis Market, by Mechanism Of Action

  • 8.1. Introduction
  • 8.2. Cyclooxygenase Inhibitors
  • 8.3. Tumor Necrosis Factor Inhibitors

9. Ankylosing Spondylitis Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral

10. Ankylosing Spondylitis Market, by Dosage Forms

  • 10.1. Introduction
  • 10.2. Liquid
  • 10.3. Solid

11. Ankylosing Spondylitis Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Hospitals

12. Americas Ankylosing Spondylitis Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Ankylosing Spondylitis Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Ankylosing Spondylitis Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
  • 15.2. Market Share Analysis, By Key Player
  • 15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

  • 16.1. Key Company Profiles
    • 16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
    • 16.1.2. Boehringer Ingelheim International GmbH
    • 16.1.3. Bristol-Myers Squibb
    • 16.1.4. Celltrion Healthcare Co.,Ltd.
    • 16.1.5. Eisai Co., Ltd
    • 16.1.6. Eli Lilly and Company
    • 16.1.7. Hetero Drugs Limited
    • 16.1.8. Novartis AG
    • 16.1.9. Reliance Life Sciences
    • 16.1.10. Samsung Bioepis Co., Ltd.
    • 16.1.11. Sandoz International GmbH
    • 16.1.12. Sanofi-Aventis Groupe S.A.
    • 16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
    • 16.1.14. Trinity Biotech PLC
    • 16.1.15. Xian Janssen Pharmaceutical Ltd
  • 16.2. Key Product Portfolio

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing